Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Indolent B-Cell Lymphomas: Clinical Application of New Advances in Community Practice
  • CME
  • CE

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: August 3, 2022 Expiration: August 2, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Incyte Corporation
Elizabeth Brém, MD
Program Director
Christopher R. Flowers, MD, MS
Program Director
person default
Pallawi Torka, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Order and interpret molecular profiling for appropriate patients with indolent B-cell lymphoma to guide therapy selection
  • Select treatment regimens for patients with MZL and FL based on available clinical data, disease characteristics, and individual patient goals and preferences to optimize clinical outcomes
  • Identify patients with indolent B-cell lymphoma who would likely benefit from enrollment on a clinical trial
  • Mitigate, monitor, and manage adverse events associated with newer therapeutic regimens used in the treatment of indolent B-cell lymphomas

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Elizabeth Brém, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
School of Medicine
University of California Irvine Medical Center
Orange, California

Elizabeth Brém, MD: consultant/advisor/speaker: Acrotech Biopharma, TG Therapeutics; advisory board: ADC Therapeutics, BeiGene, Incyte, Janssen, Kite, MorphoSys, Pharmacyclics; speaker bureau: BeiGene, Incyte, Janssen, MorphoSys, Pharmacyclics, SeaGen.
Christopher R. Flowers, MD, MS

Department Chair, Department of Lymphoma/Myeloma
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Christopher R. Flowers, MD, MS: consultant/advisor/speaker: AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Celgene, Curio, Denovo Biopharma, Epizyme/Incyte, Genentech/Roche, Genmab, MEI Pharmaceuticals, MorphoSys AG, Pharmacyclics/Janssen, SeaGen; researcher: 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD, Genentech/Roche, Gilead, Guardant, Iovance, Janssen, Kite, MorphoSys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm.

Faculty

Pallawi Torka, MD

Assistant Professor of Oncology
Lymphoma Division
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Pallawi Torka, MD: advisory board: ADC Therapeutics, Genentech, Kura Oncology, TG Therapeutics.

Staff

Jacqueline L. Olin, MS, Pharm.D., BCPS, FASHP, FCC
Jacqueline L. Olin, MS, PharmD, BCPS, FASHP, FCC, has no relevant financial relationships to disclose.
Kristen Rosenthal, PhD

Associate Director, Scientific Services

Kristen Rosenthal, PhD, has no relevant financial relationships to disclose.
Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant financial relationships to disclose.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD has no relevant financial relationships to disclose.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD has no relevant financial relationships to disclose.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant financial relationships to disclose.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant financial relationships to disclose.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant financial relationships to disclose.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD has no relevant financial relationships to disclose.
Kristi Kay Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Orbaugh, MSN, NP, AOCNP: speaker bureau: AstraZeneca, Bristol-Myers Squibb, DSI, Gilead Sciences, Lilly, Morphosys, Pfizer, Regeneron, Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for hematologists, medical oncologists, nurses, pharmacists, and other healthcare professionals who treat and manage patients with indolent B-cell lymphomas.

Goal

The goal of this program is to improve the knowledge, confidence, and competence of learners in selecting individualized treatments for patients with indolent B-cell lymphomas.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category I Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-188-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 03, 2022, through August 02, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Indolent B-Cell Lymphomas: Clinical Application of New Advances in Community Practice
  • CME
  • CE

Loading...
Watch this on-demand webcast of a live webinar for expert discussion of how community practitioners can optimize therapy selection and manage treatment-related adverse events in patients with indolent B-cell lymphomas, such as marginal zone lymphoma and follicular lymphoma.
Elizabeth Brém, MD
Program Director
Christopher R. Flowers, MD, MS
Program Director
person default
Pallawi Torka, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: August 3, 2022 Expiration: August 2, 2023

Related Content

Downloadable slideset from Antonio Urbina, MD, on HIV infection in the transgender population, including strategies for improving patient care and PrEP uptake, from Clinical Care Options (CCO)

Antonio E. Urbina, MD Released: September 27, 2022

Antonio Urbina, MD, discusses HIV infection in the transgender population, including strategies for improving patient care and PrEP uptake, from Clinical Care Options (CCO)

Antonio E. Urbina, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: September 27, 2022 Expired: September 26, 2023

Enter the characteristics of your patient with CLL into an online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Farrukh T. Awan, MD Jennifer R. Brown, MD, PhD Nicole Lamanna, MD Anthony Mato, MD, MSCE Jeff Sharman, MD Released: September 22, 2022

Download these expert-selected slides on anti-BCMA CAR T-cell and bispecific agents for relapsed/refractory myeloma, from Clinical Care Options (CCO).

Noopur Raje, MD Released: September 22, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Incyte Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings